{"id":"2921070","source":"DNA","title":"The Lancet: Covaxin 50 per cent effective against coronavirus","section":"India","slug":"","section_id":"2","author":"DNA Video Team","content":"Two doses of Covaxin, also known as BBV152 are only 50% effective against symptomatic coronavirus disease, the first real-world assessment of India’s indigenous COVID-19 vaccine published in The Lancet Infectious Diseases journal showed.\r","summary":"Two doses of Covaxin, also known as BBV152 are only 50% effective against symptomatic coronavirus disease, the first real-world assessment of India’s indigenous COVID-19 vaccine published in The Lancet Infectious Diseases journal showed.\r","websiteurl":"https://www.dnaindia.com/india/video-the-lancet-covaxin-50-per-cent-effective-against-coronavirus-2921070","thumbnail_url":"https://cdn.dnaindia.com/sites/default/files/styles/full/public/2021/11/25/1006842-00000003.jpg","isyoutube":"no","playtime":"","news_type":"video","videourl":"https://vodakm.zeenews.com/vod/DNA/covaccine_lancent.mp4/index.m3u8","time_stamp":"1637781002","publish_date":"Nov 25, 2021, 12:40 AM IST","modify_date":"Nov 25, 2021, 12:40 AM IST","url":"https://www.dnaindia.com/pwaapi/videodetail?newsid=2921070"}

Source: dna November 24, 2021 21:19 UTC